HDAC6 and pulmonary arterial hypertension: We noted that immunoreactivity for HDAC6 was considerably stronger in the lungs from PAH patients compared to the control lungs with a marked increase in PASMCs from the remodeled distal pulmonary arteries, as observed by the high degree of overlap between these two staining patterns (Fig. 1B).